These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19638702)

  • 1. [Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
    Asano S; Suzuki A; Itoh M
    Clin Calcium; 2009 Aug; 19(8):1179-85. PubMed ID: 19638702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
    Okazaki R
    Clin Calcium; 2009 Jan; 19(1):30-6. PubMed ID: 19122262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
    Kishimoto H
    Clin Calcium; 2008 Oct; 18(10):1417-26. PubMed ID: 18830038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.
    Li YT; Cai HF; Zhang ZL
    Osteoporos Int; 2015 Feb; 26(2):431-41. PubMed ID: 25266485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
    Iizuka T; Matsukawa M
    Climacteric; 2008 Aug; 11(4):287-95. PubMed ID: 18645694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New development in bisphosphonate treatment. Fracture prevention by bisphosphonates].
    Hosoi T
    Clin Calcium; 2009 Jan; 19(1):11-8. PubMed ID: 19122260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
    Tang SY; Allen MR; Phipps R; Burr DB; Vashishth D
    Osteoporos Int; 2009 Jun; 20(6):887-94. PubMed ID: 18850239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisphosphonate therapy for osteoporosis and bone strength].
    Kishimoto H
    Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
    Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
    Christoffersen H; Holmegaard SN
    Ugeskr Laeger; 2005 Nov; 167(47):4454-6. PubMed ID: 16305763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment goals of osteoporosis].
    Hosoi T
    Clin Calcium; 2014 Mar; 24(3):385-9. PubMed ID: 24576935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].
    Fukunaga M
    Clin Calcium; 2009 Jan; 19(1):63-73. PubMed ID: 19122266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
    Kishimoto H
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():365-8. PubMed ID: 18161133
    [No Abstract]   [Full Text] [Related]  

  • 18. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
    Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
    Khedr NF; El-Ashmawy NE; El-Bahrawy HA; Haggag AA; El-Abd EE
    Fundam Clin Pharmacol; 2013 Oct; 27(5):526-34. PubMed ID: 22762129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.